Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a ...
In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated steatohepatitis (MASH) is now annualizing at more than $1 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback